ReviewCureus2026
Xanomeline-Trospium Chloride as a New Paradigm in the Treatment of Schizophrenia Through Muscarinic Modulation: A Renewed Hope in Psychiatric Care.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond dopamine: KarXT and emerging mechanism-based therapies in schizophrenia.Frontiers in psychiatry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia remains one of the most challenging clinical issues, despite the efforts made and the number of treatments available to date. This review examines xanomeline-trospium chloride, a novel therapeutic approach to treating schizophrenia by targeting muscarinic acetylcholine receptors (mAChRs). The drug consists of xanomeline, a selective M1/M4 receptor agonist, and trospium, a peripheral muscarinic antagonist, which are used, respectively, to meet central therapeutic needs and avoid peripheral side effects. Xanomeline-trospium chloride has demonstrated clinical efficacy. Moreover, xanomeline-trospium chloride exhibited a better safety profile compared to prior agents, with no major metabolic impact and low discontinuation rates. However, studies show transient mild to moderate gastrointestinal effects. Nevertheless, the clinical trials of this drug have shown that it is effective and well tolerated. Although xanomeline-trospium chloride is already approved for the treatment of schizophrenia, particularly for patients who need better metabolic and cognitive outcomes, future studies should aim to investigate its efficacy in treatment-resistant schizophrenia, early-stage intervention, and other neuropsychiatric disorders. This review aims to integrate the current evidence and assess the potential of xanomeline-trospium chloride as a novel therapeutic approach in the management of schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.